Quality of life during immunotherapy in cancer patients with and without type 2 diabetes
Compares how quality of life changes during immunotherapy in cancer patients with and without diabetes.
Plain-language title generated from the registry record
Registry title: QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy
Key facts
- Where
- Aalborg, Aarhus, Herlev, and Vejle, DenmarkSee the 4 sites
Where in Denmark
- Onkologisk afdeling, Klinik Kirurgi og KræftbehandlingAalborg, DenmarkNot yet recruiting
- Kræftafdelingen, Aarhus UniversitetshospitalAarhus, DenmarkTaking people
- Afdeling for Kræftbehandling, Herlev HospitalHerlev, DenmarkTaking people
- Sygehus Lillebælt, Onkologisk afdeling VejleVejle, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Odense University Hospital
- Trial code
- NCT07466212
- Record updated
- 22 October 2026
- Original description
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is:Read full original descriptionShow less
Impact of Concurrent Diabetes on Quality-of-life Changes During Immunotherapy - A Prospective Longitudinal Study
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is:
- How does quality of life change over six months in patients with versus without diabetes?
Participants will complete quality-of-life surveys at the start, then at 3 and 6 months. This will help us see if diabetes adds extra challenges during cancer treatment
Inclusion: Age ≥18 years; Histologically confirmed solid malignant tumor; Planned treatment with ICI monotherapy or dual-ICI combination therapy (metastatic, adjuvant, or neo-adjuvant settings); Previous systemic anticancer therapy other than ICI is allowed; Ability and willingness to provide written informed consent and to complete HRQoL questionnaires; Sufficient Danish language proficiency to read, and complete study questionnaires.
Exclusion: Previous ICI treatment within 6 months; Concurrent systemic anticancer therapy other than ICI; Cognitive or physical impairment preventing valid consent or completion of patient-reported outcomes; Declines or does not provide informed consent.